Form 4: Vaxcyte CFO Andrew Guggenhime Reports Equity Grants

Vaxcyte's President and CFO, Andrew Guggenhime, reported the acquisition of restricted stock units and stock options, alongside shares disposed for tax obligations.

Summary

• Andrew Guggenhime, President and CFO of Vaxcyte, Inc. (PCVX), reported changes in his beneficial ownership.
• On February 26, 2026, Guggenhime was granted 44,864 Restricted Stock Units (RSUs) at a price of $0. These RSUs will vest 1/4 on September 7, 2026, and 1/8 every six months thereafter, subject to continuous service.
• Also on February 26, 2026, he was granted 74,993 stock options with an exercise price of $60. These options vest 1/48 monthly starting March 26, 2026, and expire on February 26, 2036.
• Shares were surrendered to cover applicable tax withholding obligations realized upon the vesting of RSUs: 898 shares on February 28, 2026, and 1,009 shares on March 2, 2026, both at a price of $61.98 per share.
• Following these transactions, Guggenhime directly owns 105,416 shares of Common Stock and indirectly owns 61,850 shares through ALG 2025 GRAT HOLDINGS LLC.
• He also beneficially owns 74,993 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates continued executive alignment with shareholder interests through significant equity grants, which is a standard and healthy practice for executive compensation.

Positives

• Grant of 44,864 Restricted Stock Units (RSUs) at a $0 price, aligning executive incentives with long-term shareholder value.
• Grant of 74,993 stock options with an exercise price of $60, providing potential upside if the company's stock price increases.

Negatives

• Disposal of 1,907 shares (898 + 1,009) of common stock at $61.98 to cover tax withholding obligations, which reduces direct ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance, focusing solely on insider equity transactions.

Industry Context

StockSavvy.ai notes that equity grants to executive officers like a President and CFO are standard practice in the biotechnology and pharmaceutical industries, serving to align management's interests with long-term shareholder value. These grants are a common component of executive compensation packages, reflecting a commitment to retaining key talent and incentivizing performance within a competitive sector.

Comparison to Industry Standards

• Equity compensation packages for executives in the biotechnology sector, such as those at Vaxcyte, often include a mix of restricted stock units and stock options.
• Similar grants are observed at comparable biopharmaceutical companies like Moderna (MRNA) or BioNTech (BNTX) for their executive teams, where significant portions of compensation are tied to long-term equity performance.
• The vesting schedules (e.g., 1/4 on a specific date, then monthly/bi-annually) are typical for encouraging sustained service and performance, aligning with common practices seen in companies developing novel vaccines or therapeutics.

Related Party Transactions

• Indirect ownership of 61,850 shares of Common Stock through ALG 2025 GRAT HOLDINGS LLC, where the Reporting Person is the annuitant and trustee of the underlying grantor retained annuity trust.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive (President and CFO) with long-term shareholder value, potentially fostering sustained performance.
• Employees: The compensation structure for executives can set a precedent or reflect the company's overall approach to incentivizing its workforce.

Next Steps

• The granted Restricted Stock Units (RSUs) will begin vesting on September 7, 2026, with 1/4 of the shares, and 1/8 every six months thereafter.
• The granted stock options will begin vesting on March 26, 2026, with 1/48 of the shares monthly thereafter.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation through equity grants and tax-related share dispositions. While the grants align management incentives with shareholder interests, these transactions are standard and do not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than these specific insider transactions.

Keywords

Vaxcyte, PCVX, Andrew Guggenhime, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Executive Compensation, Equity Grant, Beneficial Ownership